Sinovac Biotech Holds Annual General Meeting
BEIJING, April 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for March 25, 2008 was held two weeks later, on April 8, 2008. During the April 8, 2008 Annual Genera...
Sinovac Receives China State Food and Drug Administration (SFDA) Approval for Pandemic Influenza H5N1 Vaccine
BEIJING, April 2, 2008 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading China-based biopharmaceutical company focusing on human vaccine development, announced today that Panflu, its pandemic influenza H5N1 whole viron inactivated vaccine, has been granted a production lic...
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
-- Third Sequential Profitable Quarter -- -- Conference Call on Monday, March 31, 2008 at 9:00 a.m. ET -- BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced unaudited financial results for the three months an...
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Monday, March 31, 2008 at 9:00 a.m. ET to review the Company’s fourth quarter and year ended December 31, 2007 financial resu...
Sinovac Announces Adjournment of Annual General Meeting
BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for March 25, 2008 has been adjourned to April 8, 2008. At the March 25, 2008 Annual General Meeting,...
Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
BEIJING, March 24 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that Mr. Weidong Yin, CEO, Ms. Nan Wang, Vice President, Ms. Helen Yang, International Business Manager, and Ms. Vanessa Wu, Senior Financial Manager will prese...
Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
BEIJING, Feb. 19 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that it will hold its 2007 Annual Meeting of Shareholders on Tuesday, March 25, 2008 at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 3...
Sinovac Closes $9.75 Million Private Placement
BEIJING, Feb. 4 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the completion of a $9.75 million private placement of its common shares. On January 22, 2008, Sinovac entered into a share purchase agreement with Sansar Ca...
Sinovac Announces $9.75 Million Private Placement
BEIJING, Jan. 23 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it entered into a securities purchase agreement in connection with a private placement to an institutional accredited investor and, subject to standard closing ...
Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
BEIJING, Dec. 24 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced positive top-line results of completed Phase II clinical trial of its pandemic influenza (H5N1) whole viron inactivated vaccine. The stratified, randomized, double-b...
Sinovac Requests Extension for Annual Shareholders Meeting
BEIJING, Dec. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it has notified the Listing Qualifications Department at the American Stock Exchange that the Company will defer its 2007 annual stockholders meeting to no late...
Sinovac’s Hepatitis A Vaccine Healive Selected by Beijing Centers For Diseases Control and Prevention
BEIJING, Dec. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it has received confirmation from Beijing Medicine Bidding Center that Sinovac’s hepatitis A vaccine Healive was selected by the Beijing Centers For Diseases Co...
Sinovac Reports Third Quarter 2007 Unaudited Financial Results
-- Second Sequential Profitable Quarter -- -- Conference Call on Thursday, December 13, 2007 at 9:00 a.m. ET -- BEIJING, Dec. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced unaudited financial results for the three mont...
Sinovac to Hold Third Quarter 2007 Conference Call on December 13, 2007 at 9:00 A.M. ET
BEIJING, Dec. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it has scheduled a conference call on Thursday, December 13, 2007 at 9:00 a.m. E.T. (10:00 p.m. Beijing time) to review the unaudited financial results for ...
Sinovac Files Form 6-K with SEC
BEIJING, Nov. 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today filed a Form 6-K with the U.S. Securities and Exchange Commission (“SEC”) related to the inadvertent disclosure of unaudited, draft financial results for...
Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
BEIJING, Nov. 19 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced an update on the clinical trials for its pandemic influenza vaccines. Sinovac received approval in April 2007 from the China State Food and Dr...
Sinovac Enters Purchase Agreement with Beijing Public Health Bureau for Anflu, Sinovac's Seasonal Influenza Vaccine
BEIJING, Oct. 22 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has entered into an agreement with Sinovac to purchase Anflu, a split influenza vaccine developed and man...
Sinovac to Present at 2007 UBS Global Life Sciences Conference
BEIJING, Sept. 17 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading China-based biotech company focusing on human vaccine development, today announced today it is scheduled to present at the 2007 UBS Global Life Sciences Conference on Monday, September 24, 2007. Weidong Yin...
Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
BEIJING, Sept. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading China-based biopharmaceutical company focusing on human vaccine development, announced today that it has commenced vaccination of volunteers for its Phase II clinical research study of its pandemic influenza H5N...
Sinovac Announces Postponement of Annual General Meeting
BEIJING, Aug. 21 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, notified its shareholders today that the Annual General Meeting of shareholders, convened for August 21, 2007, has been postponed due the geographical nature of it...
